Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD

Inclusion Criteria:

• Male and female US Black/African American and US Hispanic participants 18 to ≤ 80years of age

• Lp(a) ≥ 125 nmol/L at the screening visit, measured at the Central laboratory

• On Standard of Care (SoC) therapy for risk factors other than Lp(a), including LDL-C (LDL-C lowering therapy dose stable for at least 30 days), elevated blood pressureand diabetes, at the randomization visit according to local practice/guidelines.

• Established ASCVD disease defined as documented:

• Coronary heart disease (CHD) and/or

• Cerebrovascular disease (CVD) and/or

• Peripheral arterial disease (PAD):

Exclusion Criteria:

• Uncontrolled hypertension

• Heart failure New York Heart Association (NYHA) class IV

• History of malignancy of any organ system

• History of hemorrhagic stroke or other major bleeding

• Platelet count <140,000 per mm3

• Active liver disease or hepatic dysfunction

• Significant kidney disease

• Pregnant or nursing women